[The intravesical chemotherapy of surface tumors of the bladder].
Intravesical chemotherapy (IVC) for bladder cancer was conducted in 83 patients who had been admitted to the Moscow Cancer Research Center in 1981-1988. Farmorubicin IVC produced a complete response (CR) in 3 (21.4%) and a partial one (PR) in 6 (42.9%) of the 14 patients treated. In mytomicin C administration CR was achieved in 4 (30.8%), PR in 2 (15.4%) of the cases. For adriamycin, spirobromin, thiotef (60 mg), thiotef (20 mg), CR was registered in 4 (30.8%), 5 (17.9%), 1 (11.1%), 2 (18.2%), 2 (25%) patients, PR in 2 (15.4%), 8 (28.6%), 1, 1 (9.1%), 1 (12.5%) patients out of 13, 28, 9, 11, 8 cases, respectively. Complications of the IVC in the form of drug cystitis occurred in 57.1%, 23.1%, 46.4%, 12.5-18.1% of those treated with farmorubicin, mytomicin C, adriamycin, thiotef, respectively. Spirobromin arose no complications.
Matveev
B P
BP
Figurin
K M
KM
Romanov
V A
VA
Burnaz
A O
AO
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000453:epidemiology; D010212:Papilloma / Q000188:drug therapy* / Q000453:epidemiology; D012074:Remission Induction; D014586:USSR / Q000453:epidemiology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000453:epidemiology
D000970:Antineoplastic Agents
Vnutripuzyrnaia khimioterapiia poverkhnostnykh opukholeĭ mochevogo puzyria.